TrialCancer2025

Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial.

Jiawei Shou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.